Nanoparticulate CpG Immunotherapy in RAO-Affected Horses: Phase I and IIa Study
Journal of Veterinary Internal Medicine2015Vol. 29(1), pp. 286–293
Citations Over TimeTop 10% of 2015 papers
John Klier, B. Lehmann, Sebastian Fuchs, Sven Reese, Astrid Hirschmann, Conrad Coester, Gerhard Winter, Heidrun Gehlen
Abstract
Administration of a GNP-bound CpG-ODN formulation caused a potent and persistent effect on allergic and inflammatory-induced clinical variables in RAO-affected horses. This treatment, therefore, provides an innovative, promising, and well-tolerated strategy beyond conventional symptomatic long-term therapy and could serve as a model for asthma treatment in humans.
Related Papers
- → Response of nitric oxide production to CpG oligodeoxynucleotides in turkey and chicken peripheral blood monocytes(2006)26 cited
- → Acute airway changes in induced by coughing(1984)2 cited
- → PROPRANOLOL INHALATION IN CHILDREN WITH ASTHMA(1985)1 cited
- Delineation of CpG motifs for activating human immune cells(2001)
- → Acute airway changes induced by coughing(1984)